Understanding how antibodies can protect against Epstein-Barr virus
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-10669738
This study is looking at how certain antibodies against the Epstein-Barr virus might help stop the virus from spreading, especially in people with weakened immune systems, like those with HIV/AIDS, and it hopes to create a safe vaccine to lower the risk of related cancers in these groups.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10669738 on ClinicalTrials.gov |
What this research studies
This research investigates the role of antibodies against the Epstein-Barr virus (EBV), particularly focusing on the gH/gL glycoprotein complex. It aims to determine whether these antibodies can prevent EBV transmission, especially in individuals who are immunocompromised, such as those living with HIV/AIDS. The study will explore the immune response generated by potential vaccines and how effectively they can block EBV infection in both B cells and epithelial cells. By examining these mechanisms, the research seeks to develop a safe and effective vaccine that could significantly reduce the risk of EBV-related lymphomas in vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV/AIDS who are at increased risk for developing EBV-related lymphomas.
Not a fit: Patients who are not immunocompromised or do not have a history of EBV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a vaccine that protects against EBV, reducing the incidence of lymphomas in immunocompromised individuals.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting other viral infections, but this specific approach to EBV is relatively novel and untested.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCGUIRE, ANDREW — FRED HUTCHINSON CANCER CENTER
- Study coordinator: MCGUIRE, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immuno-Deficiency Syndrome, Acquired Immunologic Deficiency Syndrome, Acquired Immunodeficiency Syndrome